063160.KS KSC
CKD Bio Corp.
1W: -0.2%
1M: -9.3%
3M: -5.9%
YTD: -40.2%
1Y: -44.6%
3Y: -45.4%
5Y: -78.2%
₩12,790.00 ($9.50)
+10.00 (+0.08%)
Weekly Expected Move ±2.3%
₩12211
₩12501
₩12790
₩13079
₩13369
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
-$4.1B
-129.5% ▼
Capital Expenditures
$6.8B
-58.9% ▼
5Y CAGR: -35.8%
Free Cash Flow
-$10.9B
-212.3% ▼
Dividends Paid
$549M
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$332M
+113.1% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$6.6B | -$16.7B | -$24.2B | $8.7B | -$2.9B |
| Depreciation & Amort. | $17.0B | $17.9B | $17.6B | $16.7B | $15.7B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$13.5B | -$13.9B | -$9.0B | -$12.8B | -$18.5B |
| Other Non-Cash Items | -$2.8B | $9.5B | $8.4B | $1.5B | $1.6B |
| Operating Cash Flow | -$5.9B | -$3.2B | -$7.2B | $14.0B | -$4.1B |
| — Investing Activities — | |||||
| Capital Expenditures | -$20.7B | -$7.2B | -$10.8B | -$3.4B | -$6.8B |
| Acquisitions (Net) | $220M | $33M | $18M | $0 | $8M |
| Investment Purchases | -$375M | -$13.3B | -$777M | $0 | $0 |
| Investment Sales | $650M | -$33M | $10.0B | $0 | $732K |
| Other Investing | -$176M | $33M | $375M | -$1.4B | -$150M |
| Investing Cash Flow | -$20.4B | -$20.5B | -$1.2B | -$4.8B | -$7.0B |
| — Financing Activities — | |||||
| Net Debt Issuance | $30.1B | -$7.1B | $8.1B | -$15.4B | $12.8B |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$1.1B | -$549M | $0 | $0 | -$549M |
| Other Financing | -$727M | $32.7B | -$681M | $3.6B | -$763M |
| Financing Cash Flow | $28.3B | $25.0B | $7.4B | -$11.8B | $11.4B |
| Net Change in Cash | $2.0B | $1.2B | -$1.0B | -$2.5B | $332M |
| Cash End of Period | $3.5B | $4.7B | $3.6B | $1.1B | $1.4B |
| Free Cash Flow | -$26.6B | -$10.4B | -$18.0B | $9.7B | -$10.9B |